KRX K-AI Biotech KOSDAQ Index

Voronoi’s 24-subject Phase 1 food-effect and proton-pump-inhibitor pharmacokinetic study of VRN101099 (VRN10) has an estimated primary-completion date of September 1, 2026.

AprilBio said it plans to hold its first R&D Day in late August to early September to present pipeline development, platform strategy, and the planned use of newly raised capital.

Dongkook Pharmaceutical is expected to report its June-quarter 2026 results on 18 August 2026.

Onconic Therapeutics is scheduled by market-data calendars to release its second-quarter 2026 results on August 17, 2026.

Oscotec's H1 2026 semiannual report, covering the six months ended June 30, is due by August 14, 2026 under the standard 45-day reporting deadline.

Hans Biomed's 28th-fiscal-year third-quarter report for the nine months ended June 30, 2026 is due by August 14, 2026.

Peptron is due to file its 2026 first-half report by August 14, 2026, providing the next scheduled company financial and operating update before September 7.

Vieworks remains due to file its H1 2026 interim report by 14 August 2026, which will validate or revise the preliminary first-half results released on 3 August.

LigaChem Biosciences’ 2026 half-year report is due by August 14, 2026 under the Korean disclosure schedule for December fiscal-year issuers.

AbClon's statutory deadline to file its 2026 first-half report, including June-quarter financial results, is August 14, 2026.

Alteogen’s 2026 first-half semiannual report is due by August 14, 2026 under Korea’s periodic-disclosure deadline.

Caregen is due to file its 2026 first-half report by August 14, 2026, providing its first disclosed financial update for the April–June period.

OliX is expected to release its second-quarter 2026 financial results on August 14, 2026.

L&C Bio's H1 2026 periodic report, containing Q2 financial results, is due by 14 August 2026 under Korea's 45-day post-half-year reporting requirement.

Voronoi is due to file its 2026 first-half semiannual report by August 14, 2026.

D&D Pharmatech is expected to file its 2026 first-half report by August 14, 2026, providing updated financial results, cash position, and pipeline-development disclosures.

AprilBio is due to file its 2026 half-year report, containing second-quarter financial results, by August 14.

G2GBIO is due to file its 2026 first-half report by 14 August 2026.

Rznomics is required to submit its 2026 first-half report by August 14, 2026.

Seegene formally scheduled release of preliminary consolidated Q2 and first-half 2026 results for August 7, 2026, followed by an analyst conference call.

Hugel officially scheduled its preliminary consolidated K-IFRS second-quarter 2026 results release and analyst conference call for 6 August 2026, replacing the previously reported 18 August third-party calendar date.

Alteogen announced an exclusive ALT-B4 license for subcutaneous development and commercialization of one partner product, with potential upfront and milestone payments of up to USD 365 million plus royalties.

AbClon won an KRW 824.43 million supply contract for residual-pesticide reference standards and related items for the National Institute of Food and Drug Safety Evaluation, running through December 31, 2026.

OliX extended the outside date for its Key2Brain CNS-delivery technology evaluation and option agreement from March 31, 2027 to December 31, 2027 following an adjustment to the detailed experimental schedule.

IDWeek 2026's late-breaker abstract deadline passed on August 4, making September 1 title publication and September 10 notification dates the next potential confirmation points for ST Pharm's planned October STP0404 Phase 2a presentation.

Vieworks disclosed preliminary Q2 2026 consolidated revenue of KRW 63.9 billion and operating profit of KRW 10.7 billion, with operating profit up 63.8% year on year.

L&C Bio filed a KRW140.6 billion rights-offering registration statement to finance its Dongtan smart manufacturing center, retire convertible debt, and provide working capital.

G2GBIO expects to receive the GB-5001 Phase 1 clinical study report in August 2026 and then disclose the full detailed data.

AbClon extended the end date of its KRW 424.1 million reagent and laboratory-equipment supply contract with the National Institute of Food and Drug Safety Evaluation from July 31 to September 30, 2026.

OliX shareholders approved both the registered-director compensation regulation and ratification of the 60,000-share option grant at the July 30 extraordinary meeting.

Hong Kong’s Department of Health approved an amendment to Voronoi’s global Phase 1/2 VRN110755 (VRN11) trial in EGFR-mutant NSCLC.